Selected Grantee Publications

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

Gilbert et al., Science. 2022.

https://pubmed.ncbi.nlm.nih.gov/34812653/

Investigators determined that antibodies are the correlate of protection in vaccinated individuals enrolled in the Moderna coronavirus efficacy phase 3 clinical trial. Vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection. All markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. These results help define immune marker correlates of protection and may guide approval decisions for messenger RNA (mRNA) COVID-19 vaccines and other COVID-19 vaccines. Supported by ORIP (S10OD028685).